TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05386056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinoporphyrin Sodium
Description: 0.2mg/kg, intravenously on day -2 of cycle 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
Study: NCT05456165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-C901
Description: An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R902
Description: An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Administered according to standard of care.
Study: NCT05683756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Parent Behavioral Intervention
Description: PBI administered in pediatric primary care by an embedded therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-Focused Parent Behavioral Intervention
Description: SF-PBI administered in pediatric primary care by an embedded therapist.
Study: NCT05456165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Administered according to standard of care.
Study: NCT05850065

Intervention type: OTHER
Group type: OTHER
Intervention: Hu-Friedy 212 clamp
Description: Hu-Friedy 212 clamp is normally used for the retraction with rubber-dam

Intervention type: OTHER
Group type: OTHER
Intervention: Hu-Friedy 212 clamp
Description: Hu-Friedy 212 clamp is normally used for the retraction with rubber-dam

Intervention type: OTHER
Group type: OTHER
Intervention: dental floss using the simple knot tie method
Description: Dental floss using the simple knot tie method is normally used for the retraction with rubber-dam

Intervention type: OTHER
Group type: OTHER
Intervention: dental floss using the simple knot tie method
Description: Dental floss using the simple knot tie method is normally used for the retraction with rubber-dam

Intervention type: OTHER
Group type: OTHER
Intervention: Coltene B4 clamp
Description: Coltene B4 clamp is normally used for the retraction with rubber-dam
Study: NCT06198283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level LASER Therapy with Pressure Garment
Description: This group will be treated by low level laser therapy with pressure garment (8-10hrs a day) by Laplace' s Law method because it is more accurate since the range of pressures that can be delivered to a particular range of body circumferences varies depending on the fabric used and its particular tension- extension profile, the method is difficult to utilize manually and till present there is no available design tool to aid in its application. Pressure garments generate an increase in subdermal pressures in the range 9- 90 mmHg depending on the anatomical site. Garments over soft tissues generate pressures ranging from 9 to 33 mmHg. Over bony prominences the pressures range from 47 to 90 mmHg. 25mmHg pressure will be provided by garments and garments will be replaced in every 2 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Level LASER Therapy without Pressure Garment
Description: This group will receive low level LASER therapy (422-800nm) without pressure garment only for the duration of 6 weeks (3 days in a week with 20-30 minutes per session).
Study: NCT05994287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: The patients received aspirin in a dose of 100 mg orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: The patients received aspirin in a dose of 100 mg orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The patients received ketorolac in a dose of 90 mg mg orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The patients received ketorolac in a dose of 90 mg mg orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The patients received ketorolac in a dose of 90 mg mg orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: The patients received celecoxib in a dose of 400 mg orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: The patients received celecoxib in a dose of 400 mg orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: The patients received celecoxib in a dose of 400 mg orally daily.
Study: NCT04908228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib and obinutuzumab
Description: Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
Study: NCT05432375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Description: infusion given over 60 minutes
Study: NCT05532917

Intervention type: OTHER
Intervention: Gupta score
Description: The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (\>130 mmol/L or \>1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
Study: NCT05773443

Intervention type: DEVICE
Intervention: Digital biomarkers
Description: Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor

Intervention type: DEVICE
Intervention: Digital biomarkers
Description: Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor

Intervention type: DEVICE
Intervention: Digital biomarkers
Description: Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
Study: NCT05975879

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)
Description: Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals.
Study: NCT05686356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: NAC will be given at a dose of 1800 mg BID in arm 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid will be given at its approved dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid will be given at its approved dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid will be given at its approved dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline will be given at its approved dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline will be given at its approved dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline will be given at its approved dose

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour
Description: Fixed dose combination tablets for TB treatment will be given at approved doses
Study: NCT04511806

Intervention type: OTHER
Intervention: Registry
Description: This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.

Intervention type: OTHER
Intervention: Registry
Description: This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
Study: NCT06628635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise involving aerobics, isometrics, and stretching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise involving aerobics, isometrics, and stretching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise involving aerobics, isometrics, and stretching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resting
Description: Resting
Study: NCT06628414

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation
Study: NCT04310059

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Materna
Description: Materna
Study: NCT05602441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VALID - diabetes supportive clubs
Description: The VALID - diabetes supportive clubs comprised diabetes classes and diabetes clubs, to highlight two prominent aspects of diabetes self-management: education and peer support.~The diabetes club meeting was held twice a month during a 9-month intervention, consisting of a focused delivery of the knowledge and discussion following the topic in the monthly class. Club meetings also included dedicated time for blood glucose testing and sharing experiences to deal with the difficulties of the periodic insurance examinations process. Finally, the club meetings provided the participants with emotional support to deal with the stigma and sadness in their daily lives.~Core messages aimed to strengthen daily self-management and boost the spiritual bond between individuals with T2D toward a healthy, happy life with T2DM. In addition, the intervention aimed to strengthen the capacities of grassroots health care workers in diabetes consultations and communication in rural communities.
Study: NCT05108909

Intervention type: DEVICE
Intervention: MRI, CT, and serum biomarkers
Description: magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.

Intervention type: DEVICE
Intervention: MRI, CT, and serum biomarkers
Description: magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
Study: NCT05975879

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Release form: capsules with an average weight of 585 mg. No active ingredients.
Study: NCT06414980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The effect of suggestion given to patients with the olfactory memory method before the surgical operation on vital signs and systemic evaluation scoring during awakening.
Study: NCT05999864

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
Study: NCT06388447

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Umbilical cord-mesenchymal stem cells
Description: One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord-mesenchymal stem cells
Description: One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic
Study: NCT06082076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meperidine
Description: If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine
Study: NCT05781269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLCKD
Description: VLCKD diet treatment with medical food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: r-MedDiet
Description: Mediterranean diet treatment
Study: NCT05400746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs48/45 in Matrix-M
Description: Three doses of Pfs48/45 in Matrix-M at different doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs48/45 in Matrix-M
Description: Three doses of Pfs48/45 in Matrix-M at different doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs48/45 in Matrix-M
Description: Three doses of Pfs48/45 in Matrix-M at different doses
Study: NCT05528536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Art
Description: To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: treatment as usual within their community centres
Study: NCT06141577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI059
Description: take UI059 1cap/day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UIC202201
Description: take UIC202201 1cap/day for 7 days
Study: NCT05268198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR002
Description: Active Investigational Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04729244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Hemp Oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Hemp Oil
Study: NCT04784013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CLOSE-guided pulmonary vein isolation
Description: Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High power short duration pulmonary vein isolation
Description: Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
Study: NCT05579886

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Daily disposable multifocal soft lens with 2 add design (2ADD) for 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: Daily disposable multifocal soft lens with 3 add design (3ADD) for 2 weeks
Study: NCT05108909

Intervention type: DEVICE
Intervention: MRI, CT, and serum biomarkers
Description: magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
Study: NCT05009823

Intervention type: DIETARY_SUPPLEMENT
Intervention: Standard F75
Description: F-75 contains 75 kcal and 0.9 g protein per 100 ml.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Alternative F75 With CMV
Description: Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Alternative F75 Without CMV
Description: Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.

Intervention type: DIETARY_SUPPLEMENT
Intervention: F100
Description: 100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Standard F75 + RUTF
Description: Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive

Intervention type: DIETARY_SUPPLEMENT
Intervention: Alternative F75 with CMV + RUTF
Description: Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase

Intervention type: DIETARY_SUPPLEMENT
Intervention: Alternative F75 without CMV + RUTF
Description: Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
Study: NCT05618457

Intervention type: DRUG
Group type: OTHER
Intervention: Aminoglycoside dose adjustment
Description: Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
Study: NCT04783181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV BBP-631
Description: intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV BBP-631
Description: intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV BBP-631
Description: intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV BBP-631
Description: intravenous
Study: NCT05402891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.
Study: NCT05868941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broncho Muco Cleaner
Description: The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract.~In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally.
Study: NCT06607731

Intervention type: OTHER
Intervention: Collecting data from medical records
Description: Data collected: clinical data (particularly pain), biological data, imaging.